Your browser doesn't support javascript.
loading
The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
Qu, X Melody; Velker, Vikram M; Leung, Eric; Kwon, Janice S; Elshaikh, Mohamed A; Kong, Iwa; Logie, Natalie A; Mendez, Lucas C; van der Putten, Louis J; Donovan, Elysia K; Munkarah, Adnan R; Wiebe, Ericka M; Parra-Herran, Carlos; Warner, Andrew; Louie, Alexander V; D'Souza, David P.
Afiliação
  • Qu XM; Department of Oncology, Queen's University, Kingston K7L 5P9, Canada.
  • Velker VM; Department of Radiation Oncology, London Regional Cancer Program, Western University, London N6A 5W9, Canada.
  • Leung E; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto M4N 3M5, Canada.
  • Kwon JS; Department of Obstetrics & Gynaecology, University of British Columbia, Vancouver V6Z 2K8, Canada.
  • Elshaikh MA; Department of Radiation Oncology, Henry Ford Hospital, Detroit 48202, USA.
  • Kong I; Department of Oncology, McMaster University, Hamilton L8S 4L8, Canada.
  • Logie NA; Department of Oncology, University of Alberta, Edmonton T6G 2R7, Canada.
  • Mendez LC; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto M4N 3M5, Canada.
  • van der Putten LJ; Department of Obstetrics & Gynaecology, University of British Columbia, Vancouver V6Z 2K8, Canada.
  • Donovan EK; Department of Oncology, McMaster University, Hamilton L8S 4L8, Canada.
  • Munkarah AR; Department of Gynecologic Oncology, Henry Ford Hospital, Detroit 48202, USA.
  • Wiebe EM; Department of Oncology, University of Alberta, Edmonton T6G 2R7, Canada.
  • Parra-Herran C; Department of Pathology, Sunnybrook Health Sciences Centre and Odette Cancer Centre, University of Toronto, Toronto M4N 3M5, Canada.
  • Warner A; Department of Radiation Oncology, London Regional Cancer Program, Western University, London N6A 5W9, Canada.
  • Louie AV; Department of Radiation Oncology, London Regional Cancer Program, Western University, London N6A 5W9, Canada.
  • D'Souza DP; Department of Radiation Oncology, London Regional Cancer Program, Western University, London N6A 5W9, Canada. Electronic address: david.dsouza@lhsc.on.ca.
Gynecol Oncol ; 149(2): 283-290, 2018 05.
Article em En | MEDLINE | ID: mdl-29544706
OBJECTIVE: As the optimal adjuvant management of stage IA serous or clear cell endometrial cancer is controversial, a multi-institutional review was conducted with the objective of evaluating the appropriateness of various strategies including observation. METHODS: Retrospective chart reviews for 414 consecutive patients who underwent hysterectomy for FIGO stage IA endometrial cancer with serous, clear cell or mixed histology between 2004 and 2015 were conducted in 6 North American centers. Time-to-event outcomes were analyzed by Kaplan-Meier estimates, log-rank test, univariable and multivariable cox proportional hazard regression models. RESULTS: Post-operative management included observation (50%), chemotherapy and radiotherapy (RT) (27%), RT only (16%) and chemotherapy only (7%). The 178 RT patients received external beam (EBRT, 16%), vaginal vault brachytherapy (VVB, 56%) or both (28%). Among patients without any adjuvant treatment, 5-year local control (LC), disease free survival (DFS) and cancer-specific survival (CSS) were 82% (95% confidence interval: 74-88), 70% (62-78) and 90% (82-94), respectively. CSS in patients without adjuvant treatment was improved with adequate surgical staging (100% vs. 87% (77-92), log-rank p=0.022). Adjuvant VVB was associated with improved LC (5-year 96% (91-99) vs. 84% (76-89), log-rank p=0.007) and DFS (5-year 79% (66-88) vs. 71% (63-77), log-rank p=0.033). Adjuvant chemotherapy was associated with better LC (5-year 96% (90-98) vs. 84% (77-89), log-rank p=0.014) and DFS (5-year 84% (74-91) vs. 69% (61-76), log-rank p=0.009). On multivariable analysis, adjuvant chemotherapy and VVB were associated with improved LC while adjuvant chemotherapy and age were significant for DFS. CONCLUSIONS: In stage IA serous or clear cell uterine cancer, adjuvant RT and chemotherapy were associated with better LC and DFS. Observation may be appropriate in patients who have had adequate surgical staging.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Uterinas / Cistadenocarcinoma Seroso / Adenocarcinoma de Células Claras Tipo de estudo: Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Uterinas / Cistadenocarcinoma Seroso / Adenocarcinoma de Células Claras Tipo de estudo: Observational_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá
...